BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 25940030)

  • 1. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
    Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
    Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
    Rapoport BL; Chasen MR; Gridelli C; Urban L; Modiano MR; Schnadig ID; Poma A; Arora S; Kansra V; Schwartzberg LS; Navari RM
    Lancet Oncol; 2015 Sep; 16(9):1079-1089. PubMed ID: 26272769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
    Hesketh PJ; Schnadig ID; Schwartzberg LS; Modiano MR; Jordan K; Arora S; Powers D; Aapro M
    Cancer; 2016 Aug; 122(15):2418-25. PubMed ID: 27176138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
    Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
    Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
    Schwartzberg LS; Modiano MR; Rapoport BL; Chasen MR; Gridelli C; Urban L; Poma A; Arora S; Navari RM; Schnadig ID
    Lancet Oncol; 2015 Sep; 16(9):1071-1078. PubMed ID: 26272768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting.
    Rapoport BL
    Rev Recent Clin Trials; 2017; 12(3):193-201. PubMed ID: 28393710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting.
    Ahmed H; Hammad AM; Abushouk AI; Zidan M; Salem M; Negida A; Abdel-Daim MM
    Curr Probl Cancer; 2018; 42(2):241-255. PubMed ID: 29310827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
    Rapoport BL; Aapro M; Chasen MR; Jordan K; Navari RM; Schnadig I; Schwartzberg L
    Drug Des Devel Ther; 2017; 11():2621-2629. PubMed ID: 28919712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.
    Rapoport B; van Eeden R; Smit T
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):17-29. PubMed ID: 27894202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV).
    Rashad N; Abdel-Rahman O
    Drug Des Devel Ther; 2017; 11():947-954. PubMed ID: 28392676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rolapitant: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Heo YA; Deeks ED
    Drugs; 2017 Oct; 77(15):1687-1694. PubMed ID: 28929404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C; Slusher BS
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting.
    Wang X; Wang J; Zhang ZY; Kansra V
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):850-860. PubMed ID: 31418538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.
    Herrstedt J; Summers Y; Jordan K; von Pawel J; Jakobsen AH; Ewertz M; Chan S; Naik JD; Karthaus M; Dubey S; Davis R; Fox GM
    Support Care Cancer; 2019 Jul; 27(7):2699-2705. PubMed ID: 30488222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.
    Chasen MR; Rapoport BL
    Future Oncol; 2016 Mar; 12(6):763-78. PubMed ID: 26842387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.